Understand the source comparison
HCG versus gonadorelin, enclomiphene, and clomiphene — how do they differ?
HCG is only one of several agents used to raise testosterone while trying to preserve the testis. They differ fundamentally in where on the HPG axis they act, which drives their advantages and limitations. Understanding this map is more useful than memorizing
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- HCG is only one of several agents used to raise testosterone while trying to preserve the testis. They differ fundamentally in where on the HPG axis they act, which drives their advantages and limitations. Understanding this map is more useful than memorizing any single drug.
- HCG acts at the very bottom of the axis, directly on the Leydig-cell LHCGR — an LH mimic. It works even when the pituitary is fully suppressed, which is its defining strength.
- Gonadorelin is a GnRH (gonadotropin-releasing hormone) analog that acts at the top, on the pituitary, prompting it to release its own LH and FSH. Because native GnRH signaling is pulsatile, gonadorelin has a very short half-life and physiologically needs pulsatile delivery; continuous exposure paradoxically desensitizes the pituitary. It only works if the pituitary itself is intact.
- Enclomiphene is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM). It blocks estrogen’s negative feedback at the hypothalamus and pituitary, so the brain increases its own LH and FSH output. It is oral, and it raises the man’s own gonadotropins rather than substituting for them.
- Clomiphene is the older, mixed-isomer SERM (containing both enclomiphene and the estrogenic zuclomiphene isomer), used off-label for male hypogonadism by the same feedback-blocking mechanism as enclomiphene.
- The randomized evidence for the SERMs is worth noting because it directly parallels HCG’s fertility-sparing appeal. In a randomized phase II trial, Wiehle and colleagues showed that enclomiphene citrate raised serum testosterone comparably to a topical testosterone gel while preserving sperm concentration, whereas the testosterone-gel arm showed declining sperm counts.[10] A separate trial in obese hypogonadal men reported the same pattern — enclomiphene restored testosterone while maintaining sperm counts, unlike topical testosterone.[11] Both enclomiphene and HCG, therefore, offer a “restoration rather than replacement” strategy, but by opposite ends of the axis.
- Class
- Glycoprotein hormone (LH mimic)
- GnRH analog / peptide
- SERM (trans-isomer)
- SERM (mixed isomer)
- Site of action
- Leydig-cell LHCGR (testis)
- Pituitary GnRH receptor
- Hypothalamus / pituitary (estrogen receptor)
- Requires intact pituitary?
- No
- Yes
- Route
- Subcutaneous / intramuscular injection
- Injection (needs pulsatile delivery)
- Oral
- Raises own LH/FSH?
- No (substitutes for LH)
- Yes (stimulates release)
- Regulatory status (male)
- FDA-approved for HH & cryptorchidism; TRT-adjunct is off-label
- Off-label for male hypogonadism
- Investigational / off-label in US
- Off-label in US
- Fertility-sparing rationale
- Maintains intratesticular testosterone directly
- Restores full gonadotropin drive
- Preserves sperm counts in RCTs
- Preserves gonadotropin output
- The regulatory column deserves emphasis: only HCG carries FDA approval for specific male indications, and even that approval does not extend to its most popular current use (TRT adjunct). Gonadorelin, clomiphene, and enclomiphene are all used off-label in this context in the United States. None of this is a ranking — the “best” agent depends entirely on the individual’s diagnosis, fertility goals, and whether the pituitary is functional, which is a determination for a clinician.